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isruption of latent TGF-
 
 
 
 binding protein (LTBP)–4
expression in the mouse leads to abnormal lung
development and colorectal cancer. Lung ﬁbro-
blasts from these mice produced decreased amounts of
active TGF-
 
 
 
, whereas secretion of latent TGF-
 
 
 
 was sig-
niﬁcantly increased. Expression and secretion of TGF-
 
 
 
2
and -
 
 
 
3 increased considerably. These results suggested
that TGF-
 
 
 
 activation but not secretion would be severely
impaired in LTBP-4 
 
 
 
/
 
 
 
 ﬁbroblasts. Microarrays re-
vealed increased expression of bone morphogenic protein
(BMP)–4 and decreased expression of its inhibitor grem-
D
 
lin. This ﬁnding was accompanied by enhanced expres-
sion of BMP-4 target genes, inhibitors of differentiation 1
and 2, and increased deposition of ﬁbronectin-rich ex-
tracellular matrix. Accordingly, increased expression of
BMP-4 and decreased expression of gremlin were ob-
served in mouse lung. Transfection of LTBP-4 rescued the
 
 
 
/
 
 
 
 ﬁbroblast phenotype, while LTBP-1 was inefﬁcient.
Treatment with active TGF-
 
 
 
1 rescued BMP-4 and gremlin
expression to wild-type levels. Our results indicate that the
lack of LTBP-4–mediated targeting and activation of TGF-
 
 
 
1 leads to enhanced BMP-4 signaling in mouse lung.
 
Introduction
 
The three mammalian TGF-
 
 
 
 isoforms regulate a wide variety
of cellular processes during embryonic development and in
adult organisms (for reviews see Dunker and Krieglstein, 2000;
Massagué et al., 2000). TGF-
 
 
 
s potently inhibit cellular prolif-
eration and regulate cellular differentiation and adhesion and
ECM production and degradation. At early stages of cancer de-
velopment, TGF-
 
 
 
s can act as tumor suppressors, but as tumor
cells develop resistance to the growth inhibitory action of TGF-
 
 
 
s, they can enable tumor growth (for reviews see Dumont and
Arteaga, 2000; Derynck et al., 2001) via modulation of im-
mune functions, angiogenesis, and regulation of the ECM.
High molecular mass latent TGF-
 
 
 
 complexes contain
the 25-kD mature TGF-
 
 
 
 associated noncovalently with its
propeptide (latency-associated peptide) and a latent TGF-
 
 
 
binding protein (LTBP; for review see Saharinen et al., 1999).
Recent evidence indicates that LTBPs play important roles not
only in the secretion of TGF-
 
 
 
s (Miyazono et al., 1991) but
also in the targeting of the complexes to specific extracellular
sites and in the activation process (for reviews see Taipale et
al., 1998; Annes et al., 2003). These complexes are activated
through various mechanisms. Thrombospondin- and integrin-
mediated mechanisms are probably among the most significant
(Crawford et al., 1998; Munger et al., 1999). Activation by pro-
teolytic enzymes also appears to be important, for example,
during invasive processes (Mignatti and Rifkin, 1993).
LTBPs, together with fibrillins, constitute a family of ex-
tracellular glycoproteins, which are mainly composed of re-
peated domain structures that are important for the function of
LTBPs (for reviews see Oklu and Hesketh, 2000; Koli et al.,
2001a). For example, the LTBPs contain EGF-like repeats and
8-Cys repeats, which are involved in protein–protein interac-
tions. Proline-rich regions in the molecule provide flexibility to
the protein, are sensitive to proteolytic cleavage, and also con-
tain heparin-binding sequences that may be important for cell
recognition and matrix association (Annes et al., 2004).
Three mammalian fibrillins have been identified, of
which fibrillins-1 and -2 are major constituents of the 10-nm
microfibrils (for review see Ramirez and Pereira, 1999). Of the
four LTBP isoforms (Kanzaki et al., 1990; Moren et al., 1994;
Saharinen et al., 1998; Penttinen et al., 2002), three associ-
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ate with the small latent TGF-
 
 
 
. The third 8-Cys repeats of
LTBP-1, -3, and -4 are responsible for the covalent association
with latency-associated peptide (Saharinen and Keski-Oja, 2000).
Although LTBP-1 and -3 bind all three isoforms of TGF-
 
 
 
,
LTBP-4 associates with TGF-
 
 
 
1 only (Saharinen and Keski-
Oja, 2000). LTBP-2 does not associate with the small latent
TGF-
 
 
 
, but has functions in cell adhesion and migration
(Hyytiäinen and Keski-Oja, 2003; Vehviläinen et al., 2003).
Although there is considerable overlap in the expression pat-
terns of LTBPs, studies in knockout mice suggest that each iso-
form has a tissue-specific function. For example, LTBP-2 null
mice die early in development, probably due to defective im-
plantation (Shipley et al., 2000), LTBP-3 null mice develop
skeletal abnormalities (Dabovic et al., 2002), and LTBP-4 hy-
pomorphic mice develop severe pulmonary aplasia/emphysema
and colorectal cancer (Sterner-Kock et al., 2002).
Tissue-specific abnormalities in mice expressing nearly
null alleles of LTBP-4 (
 
 
 
/
 
 
 
) are associated with defects in
elastic fiber structure and reduced levels of TGF-
 
 
 
 signaling
(Sterner-Kock et al., 2002). However, although defective TGF-
 
 
 
signaling causes cancer in both humans and mice, and is con-
sistent with the development of colorectal cancers in the ab-
sence of LTBP-4, its contribution to abnormal lung develop-
ment is still unclear. To better understand the molecular
changes associated with reduced LTBP-4 expression, we have
isolated lung fibroblasts from LTBP-4 
 
 
 
/
 
 
 
 mice and com-
pared them with wild-type (wt) fibroblasts. The most prominent
changes observed were decreased production of active TGF-
 
 
 
and increased accumulation of fibronectin-rich ECM. The de-
crease in active TGF-
 
 
 
 was associated with increased secretion
of latent forms of TGF-
 
 
 
, which suggests defects in activation
but not in secretion. Lack of LTBP-4–mediated TGF-
 
 
 
1 activa-
tion was followed by enhanced secretion of latent TGF-
 
 
 
2 and
-
 
 
 
3 and the activation of the bone morphogenic protein
(BMP)–4 signaling pathway both in vitro and in vivo. Increased
accumulation of ECM in 
 
 
 
/
 
 
 
 fibroblasts was attributed to the
activation of the BMP-4 pathway. Our results indicate that
LTBP-4 modulates the BMP-4 signaling pathway by decreas-
ing TGF-
 
 
 
 activity, which in turn leads to reduced expression
of the BMP inhibitor gremlin. These changes may explain in
part the pulmonary aplasia/emphysema phenotype, which is a
consequence of the lack of LTBP-4 protein in the 
 
 
 
/
 
 
 
 mice.
 
Results
 
Expression and secretion of TGF-
 
 
 
 in 
lung fibroblasts
 
To determine if the functional inactivation of LTBP-4 inter-
feres with TGF-
 
 
 
 secretion and/or activation, we established
lung fibroblast cultures from wt and LTBP-4 
 
 
 
/
 
 
 
 mice
(Sterner-Kock et al., 2002). As expected, LTBP-4 mRNA was
not expressed in the 
 
 
 
/
 
 
 
 fibroblasts (Fig. 1 A). TGF-
 
 
 
 activity
was quantified from cell-conditioned medium using TGF-
 
 
 
 re-
sponsive reporter cells that produce luciferase activity in re-
sponse to TGF-
 
 
 
 (Abe et al., 1994). Fibroblast-conditioned
medium (harvested at 24 h) was incubated with the reporter
cells overnight, after which the luciferase activity was mea-
sured. The amount of active TGF-
 
 
 
 in the conditioned medium
of wt cells was 
 
 
 
50 pg/ml/10
 
6
 
 cells, whereas the amount of ac-
tive TGF-
 
 
 
 was down-regulated 
 
 
 
50% in the 
 
 
 
/
 
 
 
 fibroblasts
Figure 1. Expression and secretion of TGF-  by
mouse lung fibroblasts. (A) RT-PCR analyses of LTBP-4
mRNA levels in wt ( / ) and LTBP-4 hypomorphic
( / ) lung fibroblasts. The migration of the molecular
mass markers (bp) is shown on the left. (B) Serum-free
conditioned medium was collected from wt ( / )
and LTBP-4 hypomorphic ( / ) lung fibroblasts for
24 h, and the amount of TGF-  in medium (active
TGF- ) or heat-treated medium (total TGF- ) was ana-
lyzed. Pan-specific neutralizing antibody against TGF- 
was added as a specificity control where indicated
(anti–TGF- ). The results are expressed as relative
TGF-  activity (the activity in medium from  /  cells
equals one). The error bars represent the SEM of the
samples. (C) Total RNA was isolated from lung fibro-
blasts, and mRNA expression levels of TGF- 1–3
were analyzed by Northern blotting. The results were
quantified by phosphoimager analyses and are ex-
pressed as relative value of mRNA (see Materials and
methods). The mRNA levels in control ( / ) cells
equal one. (D) Serum-free conditioned medium was
collected from lung fibroblasts for 24 h. Aliquots of the
media were concentrated and analyzed by immuno-
blotting using specific antibodies against TGF- 1–3. 
LTBP-4 REGULATION OF TGF-
 
 
 
 AND BMP-4 ACTIVITY • KOLI ET AL.
 
125
 
(Fig. 1 B). Neutralizing anti–TGF-
 
 
 
 antibodies drastically re-
duced the activity of the medium. These results correlated well
with previous in vivo findings, which indicated significantly
less TGF-
 
 
 
 signaling in the lungs of the 
 
 
 
/
 
 
 
 mice (Sterner-
Kock et al., 2002). Latent forms of TGF-
 
 
 
 from the cell-condi-
tioned media were then activated by heat treatment (Brown et
al., 1990) and analyzed with the reporter cell system. In con-
trast to the reduced levels of active TGF-
 
 
 
, the secretion of la-
tent TGF-
 
 
 
s was prominently increased in the 
 
 
 
/
 
 
 
 fibroblasts
(Fig. 1 B). This indicated that the reduced TGF-
 
 
 
 activity can-
not be attributed to decreased secretion. The results imply that
the TGF-
 
 
 
 activation process is significantly impaired in
LTBP-4 
 
 
 
/
 
 
 
 fibroblasts, probably due to perturbed targeting.
Because the 
 
 
 
/
 
 
 
 fibroblasts secreted increased amounts
of latent TGF- , we analyzed the expression and secretion of
all three isoforms of TGF- . Northern analyses of mRNA ex-
pression indicated that TGF- 1 levels were not significantly al-
tered, whereas TGF- 2 and - 3 levels were highly up-regu-
lated in  /  fibroblasts (Fig. 1 C and see Fig. 4 C). In
accordance with mRNA data, their protein levels were clearly
up-regulated (Fig. 1 D), whereas the total levels of TGF- 1 did
not change appreciably. Although the mechanism of this induc-
tion is unclear, one possible explanation is that low levels of
TGF- 1 secretion induced up-regulation of the other isoforms.
Importantly, TGF- 1 is a potent repressor of TGF- 2 and - 3
expression (Bascom et al., 1989).
LTBP-4  /  fibroblasts produce 
increased amounts of ECM
TGF- 1 is a potent regulator of ECM production and degrada-
tion that generally causes an accumulation of ECM. Therefore,
we analyzed whether or not the lack of LTBP-4–mediated
TGF- 1 targeting would reduce ECM production. Cells were
metabolically labeled for 2 d, after which extracellular matrices
were prepared and analyzed by SDS-PAGE. Unexpectedly, the
amount of sodium deoxycholate–resistant matrix was consider-
ably higher in  /  fibroblasts (Fig. 2 A), and the amount of
the 250-kD fibronectin polypeptide was particularly increased.
Immunofluorescence analyses of 5-d-old fibroblast cultures in-
dicated that in wt cells, fibronectin was localized into fibrillar
structures in the matrices, whereas in  /  cells fibronectin
was more abundant and formed a uniform sheetlike structure
around the cells (Fig. 2 B). Because the altered ECM structure
may change the sodium deoxycholate solubility of the ECM-
Figure 2. Loss of LTBP-4 results in increased produc-
tion of ECM in cultured fibroblasts and in vivo mouse
lung. (A) Lung fibroblasts were cultured in the pres-
ence of labeled amino acids for 2 d followed by iso-
lation of sodium deoxycholate insoluble matrices
(ECM). Polypeptides of the ECM preparations were
separated by SDS-PAGE under reducing conditions
and visualized by fluorography. The migration of fi-
bronectin (FN) and plasminogen activator inhibitor-1
(PAI-1) and the molecular mass markers (kD) are indi-
cated. (B) Lung fibroblasts were cultured for 5 d on
class coverslips, after which they were fixed with
methanol ( 20 C) and stained for fibronectin. (C)
Lung sections from the mice were stained for fibronec-
tin and fibrillin-1. Positive staining is reddish-brown.
(D) Total RNA was isolated from cultured lung fibro-
blasts, and mRNA expression levels of connective tis-
sue growth factor (CTGF), matrix metalloproteinase–2
(MMP-2), FN, and PAI-1 were analyzed by Northern
blotting. mRNA expression of a constant gene, glycer-
aldehyde-3-phosphate dehydrogenase (GADPH), was
used to control loading.JCB • VOLUME 167 • NUMBER 1 • 2004 126
associated fibronectin, the massive increase seen in Fig. 2 A is
plausibly due to both increased protein deposition and de-
creased solubility. Neither fibronectin mRNA levels in vitro
(Fig. 2 D) or in vivo (not depicted) nor secreted protein levels
in  /  fibroblasts (not depicted) were up-regulated, suggest-
ing increased deposition and/or decreased turnover. The cell
surface expression levels of the fibronectin receptor  5 1 inte-
grin were not changed in  /  fibroblasts (unpublished data).
Accordingly, immunohistochemical analysis of lung tissues in-
dicated that fibronectin levels were highly up-regulated in the
 /  mice (Fig. 2 C). LTBP-4 binds to fibrillin-1 (Isogai et al.,
2003) and loss of fibrillin fibers in mice leads to changes in the
levels of active TGF-  (Neptune et al., 2003). Therefore, fibril-
lin-1 distribution was evaluated, but no significant changes
were observed (Fig. 2 C).
We examined whether or not the expression of certain
ECM regulatory proteins other than TGF-  would be altered
in  /  fibroblasts. These proteins included connective tis-
sue growth factor (CTGF), plasminogen activator inhibitor-1
(PAI-1), and matrix metalloproteinase (MMP)–2. CTGF be-
longs to the CCN (CTGF, cyr61, nov) family of immediate
early genes (Leask and Abraham, 2003) and its expression is
induced in several fibrotic diseases. Our Northern hybridiza-
tion analyses indicated that CTGF mRNA levels were low in
wt fibroblasts, whereas basal expression of CTGF mRNA was
increased  10-fold in  /  fibroblasts (Fig. 2 D). Addition of
TGF- 1 further increased CTGF mRNA levels in both cell
lines (unpublished data). PAI-1 is an inhibitor of plasminogen
activation, and regulation of its expression and activity effi-
ciently controls matrix turnover. Its expression was up-regu-
lated both at mRNA (Fig. 2 D) and protein levels (not de-
picted) in  /  fibroblasts, and a similar response occurred in
wt fibroblasts treated with TGF- 1 (not depicted). MMP-2 is
also regulated by TGF- . MMP-2 levels were down-regulated
below detection limit in  /  fibroblasts.
Inhibition of TGF-  signaling does not 
reverse the  /  fibroblast phenotype
Although the amount of active TGF-  in the conditioned me-
dium was decreased, the  /  fibroblasts exhibited a pheno-
type similar to TGF- –treated wt cells. TGF-  induces the
production of ECM and enhances the expression of PAI-1 and
CTGF in wt cells (unpublished data). The enhanced secretion
of latent forms of TGF-  led us to speculate whether or not
TGF-  might be activated by a distinct mechanism. For exam-
ple, direct activation of TGF-  and subsequent binding to cell
surface receptors may occur without release into the medium.
To address this possibility, TGF-  signaling was inhibited by
stable expression of a dominant-negative TGF-  type II recep-
tor ( RII) in  /  fibroblasts (see Materials and methods).
This form of the receptor lacks the kinase domain–containing
cytoplasmic tail, and is therefore unable to transduce TGF- 
signals (Wieser et al., 1993). To verify that the transgene pre-
vented TGF-  signaling, the cells were transiently transfected
with a TGF-  responsive promoter ((CAGA)12-luc; Dennler et
al., 1998), followed by overnight treatment with TGF- 1. In
 /  fibroblasts, TGF- 1 (100 pg/ml) induced the activity of
(CAGA)12-luc promoter by  30-fold, whereas in cells ex-
pressing  RII the response was almost completely lost (Fig. 3
A). Analyses of ECM production revealed that the inhibition
of TGF-  signaling in  /  fibroblasts did not lead to reversal
of the phenotype (Fig. 3 B and see Fig. 7), which suggested
that enhanced TGF-  activity is not involved in the induction
of this phenotype.
The  /  phenotype is LTBP-4 dependent
The phenotype observed in  /  fibroblasts results from multi-
ple alterations in their gene expression pattern (Fig. 1, Fig. 2,
and Table I). To determine whether or not these changes are
truly LTBP-4 dependent, we introduced LTBP-4 expression into
the  /  fibroblasts by stable transfection of hLTBP-4S/pEF-
IRES expression vector (see Materials and methods). Immuno-
blotting analyses of LTBP-4 from concentrated cell-conditioned
medium indicated that the transgene was expressed and the pro-
tein secreted by the cells (Fig. 4 A, top). Analyses of ECM pro-
duction indicated that the LTBP-4–expressing  /  cells accu-
mulated ECM components at levels almost equivalent to wt
(Fig. 4 B). As a result of this LTBP-4 expression, the mRNA
levels of CTGF, PAI-1, TGF- 2, and TGF- 3 were reduced to
wt levels or even lower (Fig. 4 C). These results suggest that the
accumulation of ECM and the specific changes in gene expres-
sion levels could be reversed by restoring LTBP-4 expression.
Next, we tested if stable expression of LTBP-1 could
substitute for LTBP-4 in the reversal of the phenotype in  / 
fibroblasts. Detectable levels of LTBP-1 were expressed in  / 
Figure 3. Inhibition of TGF-  signaling does not rescue the LTBP-4 hypo-
morphic ( / ) fibroblast phenotype. (A)  /  lung fibroblasts expressing
a dominant-negative TGF-  type II receptor (  RII) were transiently trans-
fected with (CAGA)12-luc promoter construct (see Materials and methods).
The next day (24 h after transfection), the indicated concentrations of TGF-
 1 were added to the medium and the cells were incubated overnight. Lu-
ciferase activities were measured 48 h after transfection. The activities
were normalized by comparing them with the activities of cotransfected
Renilla luciferase. The results are expressed as relative luciferase activities
(nontreated  /  fibroblast samples equal one). (B) Lung fibroblasts were
cultured in the presence of labeled amino acids for 2 d followed by isola-
tion of the ECM. Polypeptides of the ECM preparations were separated by
SDS-PAGE under reducing conditions and visualized by fluorography. The
migration of the molecular mass markers (kD) is indicated on the left.LTBP-4 REGULATION OF TGF-  AND BMP-4 ACTIVITY • KOLI ET AL. 127
fibroblasts, and highly enhanced levels were obtained by
transgene expression (Fig. 4 A, bottom). Analyses of ECM
production indicated that the overexpression of LTBP-1 did
not decrease ECM production and thus was unable to compen-
sate for the loss of LTBP-4 in  /  fibroblasts (Fig. 4 B). This
finding suggests an isoform-specific function for LTBP-4 in
lung fibroblasts.
Gene expression profiling of fibroblasts
To identify candidate genes involved in the development of the
 /  phenotype, we analyzed differentially expressed genes by
oligonucleotide microarrays for over 12,000 mouse genes com-
paring RNA from  /  and wt lung fibroblasts (see Materials
and methods). A total of 119 genes or ESTs were either up-
or down-regulated greater than threefold in  /  lung fibro-
blasts (see Online supplemental material, available at http://
www.jcb.org/cgi/content/full/jcb.200403067/DC1). The expres-
sion of LTBP-4, which was lost, served as an internal control
for the analyses. LTBP-1 and -3 were expressed at comparable
levels in wt and  /  fibroblasts, whereas LTBP-2 expression
levels were slightly enhanced in  /  fibroblasts (unpublished
data). Special attention was paid to genes regulated greater than
fivefold, genes known to be involved in the TGF-  response
pathway, genes involved in the regulation of the ECM, and
genes of growth factors or their receptors (Table I). The expres-
sion of FGF-7 was found to be down-regulated. Although FGF-7
plays a role in lung development, knockout animals have no
obvious defects in the lung (Guo et al., 1996). In addition, sev-
eral ECM components or proteases were either up- or down-
regulated in LTBP-4  /  cells, probably contributing to the en-
hanced matrix phenotype. One of the most prominent changes
was down-regulation of the expression of thrombospondin-2,
which is a matricellular protein involved in the regulation of
cell–matrix interactions (for review see Bornstein, 2001).
A prominent observation in the  /  fibroblasts was a
fivefold increase in the expression of BMP-4, in parallel with
almost complete loss of expression of the BMP inhibitor
gremlin. Northern analyses confirmed these observations (Fig.
5 A). Immunoblotting of cell-conditioned medium revealed
increased levels of BMP-4 protein in the medium of  /  fi-
broblasts (Fig. 5 B). In addition, the BMP-4 target gene inhib-
itor of differentiation (Id)2 was induced in the gene array.
Northern analyses of Id2 as well as Id1 indicated 5–10-fold
increases in expression levels (Fig. 5 A). The expression lev-
els of the BMP-4 receptors BMPR-IA (ALK-3), BMPR-IB
(ALK-6), and BMPR-II were comparable in wt and  /  fi-
broblasts (gene array analyses; unpublished data). These re-
sults suggest that BMP-4 signaling is considerably increased
in LTBP-4  /  fibroblasts.
Figure 4. Reversal of the phenotype in  / 
lung fibroblasts by stable expression of human
LTBP-4. Human LTBP-4 or LTBP-1 expression
vector was stably transfected into LTBP-4 hypo-
morphic ( / ) lung fibroblasts. (A) Serum-free
conditioned medium was collected from lung fi-
broblasts at 24 h. Aliquots of the media were
concentrated 10-fold, and LTBP-4 (LTBP-4–trans-
fected  /  fibroblasts, top) or LTBP-1 (LTBP-1–
transfected  /  fibroblasts, bottom) secretion
was analyzed by immunoblotting. The migra-
tion of the molecular mass markers (kD) is indi-
cated on the left. (B) wt ( / ),   / , and
LTBP-4– or LTBP-1–transfected  /  fibroblasts
were cultured in the presence of labeled amino
acids for 2 d followed by isolation of the ECM.
Polypeptides of the ECM preparations were
separated by SDS-PAGE under reducing condi-
tions and visualized by fluorography. The mi-
gration of the molecular mass markers (kD) is
indicated on the left. (C) Total RNA was iso-
lated from cultured lung fibroblasts, and mRNA
expression levels of CTGF, PAI-1, TGF- 2, and
TGF- 3 were analyzed by Northern blotting.
mRNA expression of a constant gene, GADPH,
was used to control loading.
Table I. A panel of selected genes expressed differentially in LTBP-4 
 /  and control wt fibroblasts
Gene Accession Fold change
Genes up-regulated in  /  fibroblasts
Id2
a AF077861 8
BMP-4
a L47480 5
IGFBP-6 X81584 6
Genes down-regulated in  /  fibroblasts
p21 (Waf1) U09507  10
c-Fos V00727 6
Mdm2 AI853375 6
IL-6 X54542 5
Laminin-2  2 chain U12147 6
PDGF-R  X04367 5
IGF-II X71922  10
Thrombospondin-2 L07803  10
Gremlin
a AF045801  10
ADAM-19 (meltrin  ) AA726223  10
FGF-7 Z22703 5
CCN-3 (Nov) Y09257  10
The GenBank accession numbers and change in expression levels (fold change)
as coupled by Genespring software array are indicated.
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Increased BMP-4 signaling in vivo in the 
lungs of LTBP-4  /  mice
To analyze whether or not BMP-4–mediated signals were ele-
vated in vivo, lung tissues were stained with antibodies against
BMP-4 and gremlin. A clear increase in BMP-4 staining was
observed in parallel with loss of expression of gremlin in  / 
lung tissues (Fig. 6). This was accompanied by increased sig-
naling, as shown by intense staining for the BMP-specific sig-
naling molecule, phosphorylated Smad1 (Fig. 6). The total lev-
els of unphosphorylated Smad1 protein in  /  and wt lungs
were comparable.
Inhibition of BMP-4 signaling partially 
rescues the  /  fibroblast phenotype
The role of increased BMP-4 levels in  /  fibroblasts was ad-
dressed by preventing BMP-4 signaling by reexpressing grem-
lin (see Materials and methods). Expression of gremlin in  / 
fibroblasts efficiently inhibited the induction of (BRE)2-luc
promoter (Korchynskyi and ten Dijke, 2002) activity by BMP-4,
indicating that the transgene was functional (Fig. 7 A). Analy-
ses of total ECM production suggested that in contrast to the
expression of the dominant-negative TGF-  type II receptor,
gremlin expression caused a significant decrease in matrix ac-
cumulation by  /  fibroblasts (Fig. 7 B). In addition, mRNA
expression levels of both CTGF and TGF- 3 decreased signifi-
cantly (Fig. 7 C), as did TGF- 2 mRNA levels. However, PAI-1
mRNA levels did not change appreciably in gremlin-express-
ing cells. These results strongly implicate BMP-4 in the devel-
opment of the  /  phenotype.
BMP-4 induces matrix production in wt 
fibroblasts
BMP-4 induces fibronectin synthesis and ECM assembly in rat
osteoblasts by increasing the synthesis and clustering of  5 1
integrins (Tang et al., 2003). To further test if BMP-4 is involved
in the regulation of ECM accumulation, we treated wt lung fi-
broblasts with increasing concentrations of BMP-4 for 2 d and
analyzed their ECM production. A dose-dependent increase in
the accumulation of ECM occurred in BMP-4–treated cells (Fig.
8 A). The role of BMP-4 in the regulation of CTGF, PAI-1,
TGF- 2, and TGF- 3 mRNA expression was then analyzed by
Northern hybridization analyses. wt fibroblasts were treated with
5 or 50 ng/ml of BMP-4 for 24 h followed by RNA isolation and
Northern analyses. BMP-4 at 50 ng/ml induced CTGF and TGF-
 3 mRNA levels three- to fourfold, whereas PAI-1 and TGF- 2
mRNA levels were unchanged (Fig. 7 B). This result is in accor-
dance with the data indicating that the inhibition of BMP-4 sig-
naling in  /  fibroblasts by reexpression of gremlin down-reg-
ulates CTGF and TGF- 3 mRNA expression levels.
TGF- 1 signaling restores BMP-4 and 
gremlin expression to wt levels
Lack of LTBP-4 in lung fibroblasts leads to decreased activa-
tion of TGF-  and increased BMP-4 signaling. To evaluate the
relationship between these changes, we analyzed whether or
not restoring TGF- 1 activity to  /  fibroblasts rescues
BMP-4 and gremlin expression to wt levels. Induced levels of
TGF-  activity are reported to up-regulate the expression of
gremlin in other cell systems (McMahon et al., 2000). To re-
store TGF- 1 activity into  /  fibroblasts, they were cultured
for 2 wk in the presence of a low concentration (0.5 ng/ml) of
TGF- 1 in normal serum-containing medium. Cells cultured in
the presence of TGF- 1 expressed wt levels of gremlin and
BMP-4 mRNAs (Fig. 9 A). The expression of gremlin was es-
pecially increased, from undetectable to high levels, which
probably controls BMP-4 signaling levels. As expected, ECM
production was significantly decreased in  /  fibroblasts after
restoration of TGF- 1 activity (Fig. 9 B).
Discussion
In our previous paper, we observed that LTBP-4  /  mice ex-
pressing only trace amounts of LTBP-4 protein develop severe
pulmonary aplasia/emphysema (Sterner-Kock et al., 2002).
The condition was already present at birth and deteriorated
over time. Histologically, the alveolar spaces were enlarged,
inflated, and significantly reduced in number. Immunohis-
tochemical analyses revealed less active TGF- 1 in the lung
tissues of  /  mice, leading to reduced levels of Smad2 phos-
phorylation. As Smad2 is a direct target of TGF-  receptor ac-
tivation, this finding indicates that a lack of LTBP-4 severely
affects the TGF-  signaling pathway. To understand the ob-
Figure 5. Expression of BMP-4, gremlin, and BMP target genes Id1 and -2
in lung fibroblasts. (A) Total RNA was isolated from wt ( / ) and LTBP-4
hypomorphic ( / ) lung fibroblasts. On the basis of microarray analy-
ses (Table I), mRNA expression levels of BMP-4, gremlin, and inhibitors of
differentiation (Id)1 and -2 were analyzed by Northern blotting. mRNA ex-
pression of the constant gene, GADPH, was used to control loading. (B)
Serum-free conditioned medium was harvested from fibroblasts at 24 h.
Aliquots of the media were concentrated 10-fold and analyzed by immu-
noblotting using a specific antibody against BMP-4. Recombinant human
BMP-4 (rhBMP-4, 1 ng) was used as a control. The migration of the molec-
ular mass markers (kD) is indicated on the left.LTBP-4 REGULATION OF TGF-  AND BMP-4 ACTIVITY • KOLI ET AL. 129
served changes in the  /  phenotype, we have isolated lung
fibroblasts from wt and LTBP-4  /  mice. We found that the
 /  fibroblasts produced increased amounts of fibronectin-
rich ECM, and the expression of numerous genes involved in
the regulation of matrix turnover was altered. The correlation
of the in vitro findings in cultured fibroblasts with the situation
in mouse lungs in vivo was evaluated by immunohistochemical
analyses of lung tissues. A clear increase in the expression of
fibronectin was observed in lung tissues from  /  mice,
which corresponds with our observations with cultured cells.
The excessive accumulation of fibronectin and the gene
expression profile of the  /  fibroblasts were very similar in
TGF- –treated wt cells. However, neutralization of TGF- 
signaling did not rescue the phenotype and ruled out the in-
volvement of enhanced levels of TGF-  in the induction of this
phenotype. In accordance with our previous in vivo findings
(Sterner-Kock et al., 2002), we observed that the amount of ac-
tive TGF-  was significantly decreased in the  /  fibroblasts.
Interestingly, the  /  fibroblasts produced increased amounts
of latent forms of TGF- . The expression and secretion of
TGF- 2 and - 3 increased considerably in  /  fibroblasts,
but the activation of TGF-  complexes was compromised.
TGF- 1 down-regulates the expression of TGF- 2 and - 3
(Bascom et al., 1989), and the lack of LTBP-4–mediated acti-
vation of TGF- 1 might contribute to the observed increase in
Figure 6. Decreased levels of gremlin and increased levels of BMP-4 and phosphorylated Smad1 in  /  lung tissue. Lung sections from wt ( / ) and
LTBP-4  /  mice were stained for BMP-4, gremlin, phosphorylated Smad1, and total Smad1. Positive staining is reddish-brown.
Figure 7. Inhibition of BMP-4 signaling pathway partially rescues the
LTBP-4 hypomorphic ( / ) fibroblast phenotype. (A)  /  lung fibro-
blasts expressing mouse gremlin ( gremlin) were transiently transfected
with (BRE)2-luc promoter, treated with indicated concentrations of BMP-4,
and analyzed for luciferase activity as in Fig. 3 (see Materials and meth-
ods). The results are expressed as relative luciferase activities (untreated
 /  fibroblast samples equal one). (B) Lung fibroblasts were cultured in
the presence of labeled amino acids for 2 d followed by isolation of the
ECM. Polypeptides of the ECM preparations were separated by SDS-
PAGE under reducing conditions and visualized by fluorography. The mi-
gration of the molecular mass markers (kD) is indicated on the left. (C) To-
tal RNA was isolated from cultured lung fibroblasts, and mRNA expres-
sion levels of CTGF, PAI-1, TGF- 2, and TGF- 3 were analyzed by
Northern blotting. mRNA expression of a constant gene, GADPH, was
used to control loading.JCB • VOLUME 167 • NUMBER 1 • 2004 130
the levels of the other isoforms. Interestingly, BMP-4 regulated
TGF- 3 levels in wt fibroblasts, so increased secretion of
BMP-4 may also regulate TGF- 3 mRNA expression in  / 
fibroblasts. Because both LTBP-1 and -3 are expressed in the
mouse lung (Yin et al., 1995; Noguera et al., 2003), they may
compensate for the loss of LTBP-4 in the secretion of the small
latent complexes. However, the pericellular locations and acti-
vation mechanisms of various complexes are likely to be dif-
ferent. This finding is supported by the observation that over-
expression of LTBP-1 in  /  fibroblasts could not substitute
for the loss of LTBP-4 in the reversal of the phenotype. Simi-
larly, isoform-specific function of LTBP-1 in TGF- 1 activa-
tion cannot be substituted by LTBP-3 in  v 6 integrin–medi-
ated activation model (Annes et al., 2004).
The microarray analyses revealed that BMP-4 expression
was induced in  /  fibroblasts in parallel with the loss of ex-
pression of its inhibitor gremlin. Activation of the BMP path-
way was also reflected by the up-regulation of BMP-4 target
genes Id1 and -2. In addition, CTGF, which was highly up-reg-
ulated in  /  fibroblasts, is a direct target of both BMP-4 and
TGF- 1 (Abreu et al., 2002). Inhibition of the BMP-4 pathway
partially rescued the  /  phenotype, further indicating the im-
portance of this signaling cascade for the development of the
LTBP-4  /  phenotype. The observations were further sup-
ported by in vivo data because immunohistochemical staining
of  /  mouse lung tissue revealed increased BMP-4 levels in
parallel with decreased gremlin levels and increased phosphor-
ylation of the BMP-specific Smad protein.
Several genes important for the development of the lung
were dysregulated in LTBP-4  /  fibroblasts. FGF-7, BMP-4,
and TGF- 1–3 have specific expression patterns in the develop-
ing lung (for review see Warburton et al., 2000). FGF-7 pro-
motes epithelial proliferation and functions as a differentiation
factor for the developing lung. However, FGF-7 null animals do
not show any detectable lung phenotype (Guo et al., 1996),
which may be due to overlapping functions of lung morphogens.
BMP-4 is an important lung morphogen and its overexpression
under the surfactant protein promoter in the lung could severely
perturb lung development (Bellusci et al., 1996). The correct tar-
geting and expression levels of these factors are crucial for lung
morphogenesis. The up-regulation of TGF-  activation in fibril-
lin-1–deficient mice led to emphysema, which was rescued by
inhibition of TGF- 1 and - 2 activities with neutralizing anti-
bodies (Neptune et al., 2003). Interestingly, the down-regula-
tion of TGF-  activation in LTBP-4  /  and  6 integrin null
mice could also lead to emphysema-like conditions in the lung
(Sterner-Kock et al., 2002; Morris et al., 2003). Although the
mechanisms differ, the correct balance of growth factor activa-
tion appears crucial for the development of the lung.
TGF-  regulates the expression of gremlin in mesangial
cells (McMahon et al., 2000). Gremlin expression levels are
drastically down-regulated in  /  fibroblasts, which probably
allows BMP-4 signaling and accumulation of the fibronectin-
rich ECM. Restoring wt levels of TGF-  activity to  /  fibro-
blasts reverts gremlin expression and reduces ECM accumula-
tion, suggesting that TGF-  is a strong regulator of gremlin
expression and BMP-4 signaling also in lung fibroblasts.
LTBP-4 affects the targeting and activation of TGF- 1 in an iso-
form-specific manner. Although the accumulation of matrix com-
Figure 8. BMP-4 induces matrix production in wt fibroblasts. (A) wt fibro-
blasts ( / ) were cultured in the presence of the indicated concentrations
of BMP-4 and labeled amino acids for 2 d, followed by isolation of the
ECM. Polypeptides of the ECM preparations were separated by SDS-
PAGE under reducing conditions and visualized by fluorography. The mi-
gration of the molecular mass markers (kD) is indicated on the left. (B) To-
tal RNA was isolated from cultured lung fibroblasts, and mRNA expres-
sion levels of CTGF, PAI-1, TGF- 2 and TGF- 3 were analyzed by
Northern blotting. mRNA expression of a constant gene, GADPH, was
used to control loading.
Figure 9. TGF- 1 stimulation restores BMP-4 and gremlin expression to
wt levels. Lung  /  fibroblasts were cultured in the presence of 0.5 ng/
ml TGF- 1 for 2 wk ( TGF- 1). (A) Total RNA was isolated from cultured
lung fibroblasts, and mRNA expression levels of gremlin and BMP-4 were
analyzed by Northern blotting. mRNA expression of a constant gene,
GADPH, was used to control loading. (B) Lung fibroblasts were cultured in
the presence of labeled amino acids for 2 d followed by isolation of the
ECM. Polypeptides of the ECM preparations were separated by SDS-
PAGE under reducing conditions and visualized by fluorography. The mi-
gration of the molecular mass markers (kD) is indicated on the left.LTBP-4 REGULATION OF TGF-  AND BMP-4 ACTIVITY • KOLI ET AL. 131
ponents is reduced in TGF- 1  /  mouse embryo fibroblasts,
mRNA levels remain unchanged for TGF- 2 and - 3 (Sudar-
shan et al., 1998). These differences may reflect the differentia-
tion status of the cells. A contribution of LTBP functions that
are independent of TGF-  in the induction of the  /  pheno-
type cannot be ruled out. Our findings suggest that TGF- 1 tar-
geting as well as LTBP-4–dependent modulation of growth
factor pathways are important for the development of the lung.
Because BMP-4 is essential for pulmonary morphogenesis, and
its transgenic overexpression produces abnormal lungs (Bel-
lusci et al., 1996), it is likely that the pulmonary aplasia/em-
physema in LTBP-4  /  mice results at least in part from the
switch from TGF-  to BMP-4 signaling.
Materials and methods
Antibodies and growth factors
Rabbit antibodies against human TGF- 1 and human LTBP-4 have been
described previously (Taipale et al., 1992; Saharinen et al., 1998). TGF-
 2, TGF- 3, fibrillin-1 (H-109), Smad1 (A-4), and BMP-4 (3H2.3) antibod-
ies were obtained from Santa Cruz Biotechnology, Inc. BMP-4 antibody
used in immunohistochemistry was obtained from R&D Systems (AF355).
Anti-fibronectin antibodies used for immunofluorescence and immunohis-
tochemistry were purchased from Sigma-Aldrich (FN-15) and Santa Cruz
Biotechnology, Inc. (N-20), respectively. P-Smad1 antibody (Persson et
al., 1998) was provided by P. ten Dijke (The Netherlands Cancer Insti-
tute, Amsterdam, Netherlands). Rabbit antibodies against human LTBP-1
(Ab39) were provided by C.-H. Heldin (Ludwig Institute for Cancer Re-
search, Uppsala, Sweden). Recombinant BMP-4 was obtained from R&D
Systems, and TGF- 1 was obtained from Oncogene Research Products.
cDNA constructs
Full-length human LTBP-4S (Saharinen et al., 1998) was cloned into pEF-
IRES-P vector (Hobbs et al., 1998) as an XhoI–EcoRI fragment generating
a construct hLTBP-4S/pEF-IRES. The dominant-negative TGF-  receptor
( RII) cDNA insert was removed from kdT RII (construct was provided by
M.G. Brattain, Roswell Park Cancer Institute, Buffalo, NY; Ko et al., 1998)
as an EcoRI–XbaI fragment and cloned into pEF-IRES-P generating a  RII/
pEF-IRES construct. mGremlin/pEF-IRES was constructed by RT-PCR amplifi-
cation of the coding sequence of mouse gremlin followed by cloning into
pEF-IRES-P as an XhoI–EcoRI fragment. The primer sequences used for the
amplification were 5 -CCGCTCGAGATGAATCGCACCGCA-3  and 5 -
GGAATTCTGACAGGCTGAATGTGC-3 . Construct pLTBP-1 has been de-
scribed previously (Saharinen and Keski-Oja, 2000).
Cell culture and transfections
Lung fibroblast cultures from adult wt and LTBP-4  /  mice were estab-
lished according to standard protocols. In brief, the lung tissues were finely
chopped, and primary explant cultures were allowed to attach and pro-
duce outgrowth for 10 d. This was followed by trypsinization of the cells,
removal of the primary explants, and culturing the cells as adherent mono-
layer cultures until confluency. During the following 10–12 wk in culture the
cells went through a “crisis” and spontaneous immortalization produced
continuous cell lines. Two separate cell lines of both wt and  /  lung fi-
broblasts were used in the studies and they produced similar results. Mv1Lu
mink lung epithelial cells (CCL64) were obtained from American Type Cul-
ture Collection. Cells were cultured in DME supplemented with 10% FCS
(Life Technologies), 100 IU/ml penicillin, and 50  g/ml streptomycin.
For stable transfection, the cells were cultured overnight in P60 cul-
ture dishes. The transfection was performed the next day using 3  g of
plasmid DNA and 9  l of FuGENE 6 transfection reagent (Roche) accord-
ing to the manufacturer’s instructions. After transfection, the cells were
washed and incubated overnight with serum containing growth medium.
The antibiotic selection was started a day after transfection with 2  g/ml
of puromycin (Sigma-Aldrich). A gradual increase of puromycin concen-
tration was performed if higher expression levels were needed.
Cells to be transiently transfected were plated in 6-well plates. The
next day, the cells were cotransfected with a total of 2  g of (CAGA)12-luc
or (BRE)2-luc promoter constructs (provided by P. ten Dijke) together with
pRL-TK (Renilla luciferase control; Promega) plasmid using FuGENE 6
transfection reagent (Roche). After 24 h, the cells were changed to serum-
free medium, and TGF- 1 or BMP-4 were added at the indicated concen-
trations. Subsequently, 48 h after transfection, the cells were lysed and
subjected to luciferase activity measurements by a Dual Luciferase Kit
(Promega) and Digene DCR-1 luminometer (MGM Instruments).
TGF-  activity assay
Mink lung epithelial cells stably transfected with a fragment of PAI-1 pro-
moter fused to luciferase gene (TMLC) were provided by D.B. Rifkin (New
York University School of Medicine, New York, NY). These cells produce
luciferase in response to TGF- . TGF-  standards and medium samples to
be assayed for TGF-  activity were analyzed as described previously (Abe
et al., 1994). The assays were performed at least three times. The results
have been presented as relative value of TGF-  activity (wt medium set as
one). The specificity was controlled by adding neutralizing pan-specific
TGF-  antibodies where indicated (AB-100-NA; R&D Systems).
Isolation of extracellular matrices
Cells were cultured in the presence of 
35S-labeled amino acids (Easy Tag
Express-[
35S]; NEN Life Sciences Products) for 2 d. Extracellular matrices
were prepared as described previously (Hedman et al., 1979; Taipale et
al., 1992). In brief, cell cultures were washed once with PBS, and then
treated three times with 0.5% sodium deoxycholate in 10 mM Tris-HCl
buffer, pH 8.0, at 0 C for 10 min. The plates were then washed again
with PBS, allowed briefly to dry, and the ECM samples were collected by
extraction with Laemmli sample buffer and heat treated at 95 C for 5 min.
Aliquots of matrix samples were separated by SDS-PAGE and the radiola-
beled proteins were visualized by fluorography.
SDS-PAGE and immunoblotting
SDS-PAGE was performed using 7.5% or 4–15% gradient Tris-HCl poly-
acrylamide gels (Bio-Rad Laboratories). Conditioned cell culture medium,
equalized according to cell number, was concentrated 10-fold using Mi-
crocon YM-10 or YM-30 centrifugal filters (Millipore) where indicated.
Electrophoretically separated proteins were transferred to nitrocellulose
membranes using semidry blotting system (Bio-Rad Laboratories). Immuno-
detection was performed as described previously (Penttinen et al., 2002).
Immunofluorescence analysis and microscopy
Cells were grown on glass coverslips for 5 d. Coverslips were washed
three times with PBS and the cells fixed in ice-cold methanol at  20 C for
15 min. After washing three times with PBS, the cells were incubated in
Dulbecco’s PBS containing 3% BSA to prevent nonspecific binding of the
antibodies. The cells were incubated with the primary antibody in Dul-
becco’s PBS for 1 h. The binding of the antibodies was detected using
FITC-conjugated secondary antibodies (Jackson ImmunoResearch Labora-
tories). The coverslips were finally washed in water, mounted on glass
slides using Vectashield anti-fading reagent (Vector Laboratories), and ex-
amined under the imaging microscope (model Axioplan 2; Carl Zeiss Mi-
croImaging, Inc.) using a 40  objective. Images were acquired with a
camera (model AxioCamHRc; Carl Zeiss MicroImaging, Inc.) and soft-
ware (AxioVision3.1; Carl Zeiss MicroImaging, Inc.).
Immunohistochemistry
Paraffin sections of mouse tissues harvested at the age of 6 wk were pre-
pared and stained using standard histology procedures. For immunostain-
ings (immunoperoxidase), the deparaffinized and rehydrated tissue slides
were first treated for 30 min with 3% H2O2 to inactivate the endogenous
peroxidases. After rinsing in ddH2O and soaking in PBS for 5–10 min, the
slides were treated with 10% (wt/vol) BSA in PBS to saturate nonspecific
protein binding sites. The slides were exposed to the specific antibodies at
4 C overnight. After removing excess antibody, the slides were treated
with appropriate biotin-labeled secondary antibodies (Dianova) at 37 C
for 60 min, and finally with HRP-labeled streptavidin (Zymed Laboratories)
at 37 C for 20 min. After washing, the slides were incubated in diami-
nobenzidine (Sigma-Aldrich) at RT for 5 min. The slides were finally exam-
ined under a conventional microscope (Carl Zeiss MicroImaging, Inc.) af-
ter removing the excess substrate in ddH2O.
RNA isolation and RT-PCR
Total cellular RNA was isolated using RNeasy Mini kit (QIAGEN) accord-
ing to manufacturer’s instructions. RNA concentrations and purities were
determined spectrophotometrically (Ultrospec 3000; Amersham Biosci-
ences) as well as by agarose gel electrophoresis followed by ethidium bro-
mide staining.
Reverse transcription was performed with Random primers (Life
Technologies) and Superscript II reverse transcriptase (Life Technologies)JCB • VOLUME 167 • NUMBER 1 • 2004 132
using 2.5  g of total RNA according to manufacturer’s instructions. The
cDNAs were amplified using AmpliTaq Gold (PerkinElmer) in a 30-cycle
PCR reaction as described previously (Koli et al., 2001b). The primer se-
quences used for the amplification of the LTBP-4 fragment were 5 -
CCCGCTCCGTTTATACAATG-3  and 5 -AGGAAACCGTCCGGAC-3 .
The amplified products were analyzed by agarose gel electrophoresis.
Northern hybridization analyses
10  g of total cellular RNA was fractionated on 1.2% agarose gels con-
taining formaldehyde and transferred to Hybond-N nylon membranes
(Amersham Biosciences) by capillary transfer. Prehybridization and hy-
bridization were performed at 68 C in ExpressHyb hybridization solution
(CLONTECH Laboratories, Inc.). cDNA probes for genes of interest and a
control gene glyceraldehyde-3-phosphate dehydrogenase (GADPH) were
labeled with [
32P]-dCTP ( 3,000 Ci/mmol; Amersham Biosciences) using
a Ready-To-Go DNA Labeling Kit (Amersham Biosciences). Radioactivity
levels were quantified with a bio-imaging analyzer (model BAS-2500;
Fuji) where indicated, and the results expressed as mRNA expression lev-
els relative to the GADPH levels.
Oligonucleotide microarray analyses
Total RNA was extracted using TRIzol (Invitrogen) according to the manu-
facturer’s instructions. To assure that the gene expression measured by mi-
croarray assay was not affected by degradation of the RNA extracted from
the lung fibroblast cells, we used the Bioanalyzer-system (Agilent Technolo-
gies) to evaluate the quality of the RNA. The protocol for the sample prepa-
ration and microarray processing was according to instructions (Affymet-
rix, Inc.). 10  g of fragmented, biotinylated cRNA was hybridized to a
MGU74Av2 microarray (Affymetrix, Inc.) for 16 h at 45 C with constant ro-
tation at 60 rpm. After hybridization, the microarray was washed and
stained on a fluidics station (Affymetrix, Inc.) and scanned with an argon-
ion confocal laser, with a 488-nm emission and detection at 570 nm. Gene-
Chip image analysis was performed using the Microarray Analysis Suite
5.0 (Affymetrix, Inc.). Data analysis was performed with the GeneSpring
software version 4.2 (Silicon Genetics Inc.). To eliminate changes within the
range of background noise and to select the most differentially expressed
genes, the restrictions used to classify genes as up- or down-regulated in-
cluded a change in expression of greater than threefold and evidence that
the genes were “present” according to the data analysis (Affymetrix, Inc.).
Online supplemental material
The complete data from the gene array analyses (see Gene array analyses)
is available at http://www.jcb.org/cgi/content/full/jcb200403067/DC1.
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